Analyst Rami Katkhuda of LifeSci Capital maintained a Buy rating on Dianthus Therapeutics, retaining the price target of $65.00.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Rami Katkhuda has given his Buy rating due to a combination of factors including Dianthus Therapeutics’ strong financial position and promising clinical developments. The company reported a robust cash position of approximately $525 million, which is projected to support operations until 2028. This financial stability provides a solid foundation for ongoing and future research initiatives.
Furthermore, the recent clinical updates, particularly from the Phase II MaGic study, indicate significant advancements in their pipeline. The results showcased encouraging improvements in patients treated with claseprubart, suggesting potential efficacy even at lower complement inhibition levels. These findings, along with plans to initiate pivotal studies, underscore the company’s strategic focus and potential for growth, justifying the Buy rating.
In another report released today, Oppenheimer also maintained a Buy rating on the stock with a $62.00 price target.